Clinical trials: Type 2 Diabetes Prevention
Coronary Atherosclerosis, Coronary Restenosis
PIoglitazone for PrEvention of Restenosis in Diabetic Patients
Restenosis requiring reintervention is still a limitation of percutaneous coronary angioplasty. Despite the use of Drug eluting stent (DES), the rate of restenosis remains 7% to 16% in diabetic patients, making it a challenging…
- Conditions
- Coronary Atherosclerosis, Coronary Restenosis, Diabetes
- Trial name
- NCT00376870
- Testing
- Pioglitazone
- Where
- 2 sites in Italy
- Volunteers
- 160 people
- Sponsor
- University of Rome Tor Vergata